Department Of Hematology And CHMO – PGIMER, Chandigarh

Department of Hematology and
Department of Clinical Hematology & Medical Oncology
Postgraduate Institute of Medical Education and Research, Chandigarh

Menu

Our Publications in 2020-21

  1. Arora N, Jandial A, Saroch A, Pavani V, Gupta N, Pannu AK, Singh C. TB, or not TB? Postgrad Med J 2020; postgradmedj-2020-138762.
  1. Goni D, Jain A, Jindal N, Nampoothiri R, Lad D, Naseem S, Prakash G, Khadwal A, Varma N, Malhotra P. Feasibility of treatment free remission with generic imatinib:
    Results of GIFT-in-CML-CP study. Authorea Preprints. 2020 Oct 1.
  1. Jain A, Deo P, Sachdeva MUS, Bose P, Lad D, Prakash G,Khadwal A, Varma N, Varma S, Malhotra P. Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. Blood Cells Mol Dis 2021 Mar 27;89:102565.
  2. Jain A, Khadwal A, Sachdeva MU, Bose P, Lad D, Bhattacharya S, Prakash G, Malhotra P, Varma N, Varma S. Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post- transplant Period? Indian J Hematol Blood Transfus 2021;37(3):484-88.
  1. Jain A, Khadwal A, Sachdeva MU, Bose P, Lad D, Bhattacharya S, Prakash G, Malhotra P, Varma N, Varma S. Variables affecting the presence of mesenchymal stromal cells in peripheral blood and their relationship with apheresis products. Br JHaematol 2020;189(4):772-6.
  1. Jain A, Singh C, Dhawan R, Jindal N, Mohindra R, Lad D, Prakash G, Khadwal A, Suri V, Bhalla A, Kumari S. How to use a prioritised approach for treating hematological disorders during the COVID-19 pandemic in India? Indian J Hematol Blood Transfus 2020;36:605-15.
  1. Jindal N, Jain A, Lad D, Prakash G, Khadwal A, Malhotra P. Dose‐adjusted EPOCH‐R: a feasible alternative for Burkitt lymphoma in resource‐constrained settings. British J Haematol 2020;190(6):e362-3.
  1. Jindal N, Lad DP, Malhotra P, Prakash G, Khadwal A, Jain A, Sachdeva MS, Sreedharanunni S, Naseem S, Varma N, Varma S. Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL. Leuk Lymph 2021;62(7):1674-81.
  1. Jindal N, Singh C, Malhotra P. Unusual cause of mediastinal widening. BMJ Case Rep 2020;13(6):e236180.
  1. Jindal N, Nampoothiri R, Rajpal S, Sreedharanunni S, Varma N, Malhotra P. Does Development of Plasmacytosis have a Role in Spontaneous Remission of Acute Myeloid Leukemia? Indian J Hematol Blood Transfus 2021;37(1):167-68.
  1. Jindal N, Malhotra P, Patil AN, Lad D. Clinical research in hematology- oncology in India uring the COVID-19 era. Indian J Med PaediatrOncol 2020;41:799-800.
  1. Kumari S, Tripathi PP, Sharma RR, Hans R, Lamba DS, Khadwal A, Singh C. Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A)–A case report. TransfusiApheresSci 2020 Aug 1;59(4):102809.
  1. Lad D, Malhotra P, Patil AN, Nampoothiri RV, ShankerKasudhan K, Khadwal A, et al. Long term outcomes of innovator versus generic melphalan in autologous hematopoietic cell transplantation for multiple myeloma. HematolOncol Stem Cell Ther 2020 Jun 25:S1658-3876(20)30113-8.
  1. Lad D. Making sense of cross-trial comparisons for the frontline treatment of advanced stage Hodgkin lymphoma. Eur J Cancer 2020;136:113-15.
  1. Lad DP, Tejaswi V, Jindal N, Malhotra P, Khadwal A, Prakash G, Jain A, Sreedharanunni S, Sachdeva MS, Naseem S, Varma N. Modified CLL international prognostic index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. LeukLymph 2020;61(6):1512- 5.
  1. Tejaswi V, Lad D, Jindal N, et al. Chronic Lymphocytic Leukemia: Real-World Data From India. JCO Glob Oncol 2020;6:866-872. doi:10.1200/GO.20.00032.
  1. Youron P, Singh C, Jindal N, Malhotra P, Khadwal A, Jain A, Prakash G, Varma N, Varma S, Lad DP. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire. EurJ Hematol 2020;105(6):755-62.
Scroll to Top